本季度信息
截至2026年6月30日，东曜药业-B实现营业收入2.46亿元，同比下降49.7%。毛利润0.53亿元，同比下降85.1%，毛利率21.4%。期内经调整净亏损0.23亿元，同比减少330.5%，对应的经调整净亏损率为9.2%。经营活动现金流量净流出0.42亿元，去年同期净流入0.35亿元。
从费用结构看，研发投入为0.27亿元，相较去年同期减少0.09亿元，主要由于产品线精简所致。销售费用0.22亿元，去年同期为2.77亿元，主要是自研产品销量下滑导致相关市场推广成本降低。一般及行政费用0.59亿元，较去年同期0.35亿元增加0.24亿元，主要和并购相关咨询费用增加有关。
业务分项
CDMO业务方面，收入达到1.99亿元，同比增长157.0%，主要由于项目数与在手业务规模明显提升。自研产品销售收入0.45亿元，同比下降88.6%，系市场竞争加剧以及国内医药集采政策推进带来的综合影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.